CCL2 and melanoma: Additionally, screening for changes in cytokines and chemokines showed an elevation in the release of specific chemokines, including regulated upon activation, normal T cell expressed and secreted (RANTES), and monocyte chemoattractant protein-1 (MCP-1) in the B78 melanoma cell line following LDHI treatment.